Australia Markets open in 3 hrs 27 mins

GeNeuro SA (GNRRF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
4.55000.0000 (0.00%)
At close: 10:33AM EDT
Full screen
Loading interactive chart…
  • Business Wire

    GeNeuro: Financial Information and Business Update for the Second Quarter 2022

    GENEVA, July 21, 2022--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), today reported on its 2022 second quarter cash position and issued a business update.

  • Business Wire

    GeNeuro: Study Confirming the Key Role of Human Endogenous Retroviruses (HERV-K) for ALS Published in "Annals of Neurology", a Leading Scientific Journal

    GENEVA, July 20, 2022--Regulatory News: GeNeuro (Paris:GNRO) (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID), announced today the publication in the leading scientific journal "Annals of Neurology" of the results of the collaboration between GeNeuro and the National Ins

  • Business Wire

    GeNeuro Will Contribute Its Expertise in Human Endogenous Retroviruses to the €6.8M EU-Funded HERVCOV Precision Medicine Project

    GENEVA & LYON, France, June 20, 2022--Regulatory News: GeNeuro (Euronext Paris: CH0308403085 - GNRO) (Paris:GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the long-term consequences of COVID-19 (post-COVID), announces today that its R&D subsidiary GeNeuro Innovation SAS will be the industrial R&D partner of the HERVCOV project funded with a €6.8 million grant from